3 completed, 2 recruiting, 2 unknown, 2 withdrawn. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 3, Recruiting 2, Unknown 2, Withdrawn 2, Terminated 1 |
Follow Soft Tissue Sarcomas: new trials by email Literature Review of Soft Tissue Sarcomas trials Research Report on Soft Tissue Sarcomas
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Tislelizumab+liposomal doxorubicin+ifosfamide - Soft Tissue Sarcomas, Angiosarcoma | Phase 2 | Recruiting | Fudan University | 45 | 2025-02-25 | 2026-01-08 |
| The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities Hypofractionated Radiotherapy, 3 cycles of AI - Soft Tissue Sarcomas | Phase 2 | Unknown | Fujian Medical University Union Hospital | 51 | 2024-05-01 | 2024-09-19 |
| Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas Ultra-Hypo-fractionation Radiotherapy, Resection, Questionnaire Administration - Soft Tissue Sarcomas | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 40 | 2021-03-02 | 2025-03-28 |
| Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Anlotinib, Toripalimab, Blood Draw - Soft Tissue Sarcomas, Undifferentiated Pleomorphic Sarcoma | Phase 2 | Unknown | Di Wu | 25 | 2019-07-19 | 2019-07-10 |
| Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas Nivolumab, Pazopanib - Soft Tissue Sarcomas | Phase 2 | Withdrawn | NYU Langone Health | 2017-08-01 | 2017-08-22 | |
| Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas Axitinib, Pembrolizumab - Alveolar Soft Part Sarcoma, Soft Tissue Sarcomas | Phase 2 | Completed | Jonathan Trent, MD, PhD | 33 | 2016-04-19 | 2024-07-12 |
| Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients external beam radiotherapy, pazopanib - Sarcoma, Soft Tissue Sarcomas | Phase 2 | Terminated | The Netherlands Cancer Institute | 25 | 2016-03-17 | 2019-06-27 |
| RAD001 in Advanced Sarcoma RAD001 - Soft Tissue Sarcomas, Bone Sarcomas | Phase 2 | Completed | Asan Medical Center | 41 | 2010-04-01 | 2013-04-12 |
| Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas Chemoradiotherapy Temozolomide, Proton therapy, Proton Chemoradiotherapy followed by surgery - Soft Tissue Sarcomas | Phase 2 | Withdrawn | University of Florida | 2009-02-01 | 2017-02-10 | |
| The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). AZD2171 - Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas | Phase 2 | Completed | AstraZeneca | 35 | 2006-09-01 | 2012-07-16 |
Sarcoma (10) · Bone Neoplasms (1) · Desmoplastic Small Round Cell Tumor (1) · Fibrosarcoma (1) · Gastrointestinal Stromal Tumors (1) · Hemangiosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Liposarcoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neurofibrosarcoma (1) · Sarcoma, Alveolar Soft Part (1)
Neoplasms by Histologic Type (10) · Neoplasms, Connective and Soft Tissue (10) · Neoplasms (9) · Neoplasms, Connective Tissue (3) · Neoplasms, Fibrous Tissue (2) · Neoplasms, Muscle Tissue (2) · Bone Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Histiocytoma (1) · Musculoskeletal Diseases (1) · Neoplasms by Site (1) · Neoplasms, Adipose Tissue (1)
Radiotherapy (2) · pazopanib (2) · Axitinib (1) · Biopsy, Needle (1) · Blood Specimen Collection (1) · Everolimus (1) · Nivolumab (1) · Phlebotomy (1) · Proton Therapy (1) · Radiation Dose Hypofractionation (1) · Temozolomide (1) · anlotinib (1) · cediranib (1) · pembrolizumab (1) · toripalimab (1)
Asan Medical Center (1) · AstraZeneca (1) · Di Wu (1) · Fudan University (1) · Fujian Medical University Union Hospital (1) · Jonathan Trent, MD, PhD (1) · NYU Langone Health (1) · The Netherlands Cancer Institute (1) · University of Florida (1) · Vanderbilt-Ingram Cancer Center (1)
China (3) · United States (3) · United Kingdom (2) · Netherlands (1) · South Korea (1)
Daniel J Indelicato, MD (1) · Eric Shinohara, MD (1) · Jane Robertson, MD (1) · Jin-Hee Ahn, MD, PhD (1) · Jonathan C Trent, MD (1) · Luca Paoluzzi (1) · Rick Haas, MD, PhD (1) · Yong Yang, Doctor (1)